Please login to the form below

Not currently logged in
Email:
Password:

Genzyme appoints MS and rare diseases business leaders

William Sibold will head the multiple sclerosis business and Rogério Vivaldi will lead rare diseases

Genzyme has appointed leaders for its core multiple sclerosis and rare diseases businesses.

William “Bill” Sibold will head the multiple sclerosis business and Rogério Vivaldi will lead rare diseases.

“These appointments are a critical step in launching the new Genzyme,” said the company's CEO David Meeker. “Bill and Rogério are dynamic leaders with the experience, energy, vision and commitment to patients needed to move us forward.”

Sibold has more than 20 years of experience in the biopharmaceutical industry, including eight years at Biogen Idec where he worked on multiple sclerosis products Avonex and Tysabri.

He joins Genzyme from Avanir Pharmaceuticals, where he was the chief commercial officer, leading all of the company's commercial activities.

Vivaldi has been with Genzyme since 1997 and was most recently president of Genzyme's renal and endocrinology business. He previously served as senior vice president and president of Genzyme Latin America.

11th November 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Madmicrobe Studios - Medical Animation

MadMicrobe is an award-winning team of certified medical illustrators creating animations that engage your audience with immersive experiences that bring...

Latest intelligence

Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
News:
Senior Analytics Specialist joins Research Partnership...
Digital technologies: Pharma’s answer to achieving net zero emissions?
...